Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194226 | 0.91 | SQOR (0.46) | SQORMAPTKDM4EPOLBATM | |
| SCHEMBL4764868 | 0.91 | PLA2G2A (0.48) | MAPTPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL3205580 | 0.86 | MEN1 (0.45) | SQORMAPTKDM4EPOLBPLA2G2A | |
| SCHEMBL3188811 | 0.79 | PLA2G2A (0.62) | PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL14531281 | 0.78 | PLA2G2A (0.45) | SQORMAPTKDM4EPOLBATM | |
| SCHEMBL3202939 | 0.78 | PLA2G2A (0.61) | SQORPLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL5762171 | 0.77 | PLA2G1B (0.42) | SQORMAPTKDM4EPOLBPLA2G2A | |
| SCHEMBL3186290 | 0.76 | TSHR (0.50) | SQORMAPTKDM4EPOLBPLA2G2A | |
| SCHEMBL2157014 | 0.76 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5PSEN1 | |
| SCHEMBL4764879 | 0.76 | PLA2G2A (0.44) | MAPTKDM4EPLA2G2AGAAPLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1960356-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | Ilypsa, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | SQOR 1578/4885MAPT 3875/4885KDM4E 415/4885 |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G5, PLA2G4A, PLA2G3 | SQOR 3254/4885MAPT 4879/4885KDM4E 1533/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | SQOR 2822/4885MAPT 4260/4885KDM4E 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.